Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities
MWN-AI** Summary
Celularity Inc. (NASDAQ: CELU) has reaffirmed its strategic partnership with NEXGEL, Inc. (NASDAQ: NXGL), focusing on the commercialization of placental-derived biomaterials. This collaboration aims to leverage renewed regulatory clarity and reimbursement policies to enhance market penetration and product sales in segments like wound care and orthopedics. Celularity will exclusively manufacture a suite of established products, including Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl, and Centaflex, at its FDA-compliant facility in Florham Park, New Jersey. These products are well-regarded in healthcare and form the foundation for their ongoing efforts.
Importantly, the partnership also includes three promising 510(k) medical device pathways—SPARK, FUSE, and ORCHID—expected to be potential disruptors in the market. Robert J. Hariri, M.D., Ph.D., Celularity’s CEO, articulated that the partnership allows the company to focus on its strengths in contract manufacturing while benefiting from NEXGEL's entrepreneurial approach to drive growth and value across various industry sectors. The transaction is expected to close by April 15, 2026, pending customary closing conditions.
Celularity specializes in regenerative and cellular medicine, utilizing postpartum placental tissue to develop therapies targeting aging and related diseases. Their vertically integrated manufacturing process supports both commercial products and the development of next-generation cellular therapeutics. The collaboration with NEXGEL symbolizes Celularity's commitment to advancing its biomaterials franchise while optimizing operational efficiencies.
Investors are urged to consider the forward-looking nature of this partnership, which carries inherent risks and uncertainties that could influence outcomes. Celularity is poised to harness its capabilities and collaboration with NEXGEL to potentially accelerate market presence and improve healthcare outcomes.
MWN-AI** Analysis
Celularity Inc. (NASDAQ: CELU) has reinforced its strategic partnership with NEXGEL, Inc. (NASDAQ: NXGL) to enhance its biomaterials franchise, which includes established products in wound care and orthopedics. This collaboration capitalizes on the increasing regulatory and reimbursement clarity around placental-derived biomaterials, a promising market segment.
The partnership is anchored by several commercial products such as Biovance, Biovance 3L, Natalin, and Acelagraft, which are already gaining traction in their respective therapeutic areas. Additionally, three innovative pipeline products—SPARK, FUSE, and ORCHID—are poised to enter the market through the 510(k) medical device pathway, potentially disrupting the current market landscape.
Celularity's commitment to being the exclusive manufacturer at its FDA-compliant facility in New Jersey underscores its capability to support both current and future product lines. This strategic operational focus allows Celularity to utilize its expertise in contract manufacturing—a core strength that enhances production scale and quality.
Investors should view this partnership as a pivotal growth catalyst for Celularity. As regulatory and market dynamics evolve favorably, the potential for revenue streams from milestone payments, royalties, and manufacturing income could significantly bolster Celularity’s financial outlook. The emphasis on efficient production in a growing biomaterials market, combined with NEXGEL’s entrepreneurial approach, could drive growth in market share.
However, investors should remain cautious regarding risks, including regulatory uncertainties and production variability. Monitoring milestones related to the successful commercialization of these products will be critical in evaluating long-term investment potential. Overall, the partnership positions Celularity favorably within the regenerative medicine landscape, presenting a compelling opportunity for growth-focused investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications.
- Three pipeline 510(k) medical device pathway programs SPARK, FUSE, and ORCHID licensed to NEXGEL are potential market disruptors.
- Celularity will be the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey, where its vertically integrated manufacturing infrastructure is designed to support scalable, quality-driven production for both commercial-stage products and next-generation placental-derived cellular therapeutics.
FLORHAM PARK, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on longevity science, today reiterated that its strategic commercialization partnership with NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL) is a focused effort by the two companies to rapidly capitalize on renewed regulatory and reimbursement clarity around placental-derived biomaterials and build sales and market share. The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions.
“This strategic deal with NEXGEL allows Celularity to focus on a core strength—contract manufacturing—where we have demonstrated over many years our ability to scale and execute cost efficient biomaterial production at a pharmaceutical-like grade,” said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer. “NEXGEL is the ideal partner to take these biomaterial products to the next level, with a disciplined, entrepreneurial approach and proven ability to drive value and market growth across industry verticals. Congratulations to the Celularity and NEXGEL teams as we look forward to closing the transaction in April.”
About Celularity
Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity leverages the placenta’s unique biology, immunologic properties, and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease.
For more information, please visit www.celularity.com.
Forward-Looking Statements
Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the anticipated closing of the strategic commercialization partnership described herein and the expected timing thereof; the potential receipt of upfront consideration, milestone payments, royalties and manufacturing revenues associated with the transaction; the anticipated operational and strategic benefits of the partnership; Celularity’s strategic focus on longevity science, scalable manufacturing infrastructure and capital efficiency; the continued development, regulatory advancement and commercialization of the licensed biomaterials portfolio and development-stage programs; and Celularity’s plans to pursue commercial and clinical opportunities for its technologies in jurisdictions that permit investigational use under applicable law.
Forward-looking statements are based on Celularity’s current expectations and assumptions regarding future events and are subject to risks, uncertainties and changes in circumstances that are difficult to predict. Words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “will,” and similar expressions are intended to identify forward-looking statements.
Actual results may differ materially from those expressed or implied in forward-looking statements as a result of various risks and uncertainties, including, without limitation, the ability of the parties to satisfy closing conditions and complete the transaction on the anticipated timeline or at all; the ability to realize anticipated financial benefits of the transaction, including milestone payments, royalties or manufacturing revenues; variability in manufacturing volumes or product demand; regulatory developments affecting the development, manufacture or commercialization of Celularity’s products; the successful execution of Celularity’s strategic realignment and organizational restructuring; the development and commercialization of Celularity’s longevity-focused therapeutic programs; and the other risks and uncertainties described under the caption “Risk Factors” in Celularity’s Annual Report on Form 10-K and Form 10-K/A for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on May 8, 2025, and May 21, 2025, respectively, and in Celularity’s other filings with the SEC.
Forward-looking statements speak only as of the date of this press release. Except as required by law, Celularity undertakes no obligation to update or revise any forward-looking statements contained herein to reflect events or circumstances occurring after the date of this press release.
Investor Contact
Carlos Ramirez, Senior Vice President, Celularity Inc.
Carlos.ramirez@celularity.com
FAQ**
How is the strategic commercialization partnership with NEXGEL expected to enhance Celularity Inc.'s position in the market for products like Biovance and Biovance 3L, and what role will the "Celularity Inc. Warrant CELUW" play in this growth?
Given the FDA-compliant facility in Florham Park, how does Celularity plan to leverage its scalable manufacturing infrastructure to support the anticipated demand for Natalin and Acelagraft, particularly in relation to "Celularity Inc. Warrant CELUW"?
What measures are in place to mitigate risks associated with the 510(k) medical device pathway programs SPARK, FUSE, and ORCHID, and how might the potential outcomes affect investors holding "Celularity Inc. Warrant CELUW"?
In light of the announcement regarding the closing of the transaction with NEXGEL by April 15, 2026, what specific benefits should investors expect from this deal, particularly those interested in "Celularity Inc. Warrant CELUW"?
**MWN-AI FAQ is based on asking OpenAI questions about Celularity Inc. (NASDAQ: CELU).
NASDAQ: CELU
CELU Trading
-9.77% G/L:
$1.20 Last:
128,960 Volume:
$1.25 Open:
